Pfizer will embed a Chai platform instance trained on proprietary datasets, signaling deeper operational integration than typical external AI service usage and potentially accelerating biologics ...

Pfizer scientists will leverage Chai Discovery’s AI platform - including Chai-3, its most advanced model - alongside custom software, to help accelerate drug discovery research SAN ...

ast June, when AI drug discovery startup Chai Discovery was just 15 months old, it released a new model that could design antibodies. Nearly 20 pharma companies reached out to talk. “It was like we ...